The 2026 cumulative-dose trial should not change adult acne care yet because the higher total did not improve treatment response. Cumulative dose means the total isotretinoin, an oral drug for severe acne, taken per kilogram of body weight across a full course, and 150 mg/kg did not beat 120 mg/kg. The trial enrolled 91 adolescents and young adults with moderate-to-severe cystic acne. That group differs from adults with persistent acne in age, hormones, and long-term relapse risk.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What did the 120-versus-150 trial test?
- Why does age matter for adults with persistent acne?
- What does large-scale relapse evidence show?
- What should adults discuss with a dermatologist now?
What did the 120-versus-150 trial test?
Researchers compared two total amounts of isotretinoin over a full course. One group aimed for 120 mg/kg and the other for 150 mg/kg. The Limbic reports no added benefit from the higher total for lesion count, severity, or 12-month relapse in the trial summary.
The question remains active. A September 2026 correspondence in the Journal of the European Academy of Dermatology and Venereology identifies the study as the Murrell group trial and debates its methods. That debate keeps the result provisional rather than final.
Why does age matter for adults with persistent acne?
Persistent acne means breakouts that continue past the teen years into adulthood. The dose trial focused mainly on adolescents and young adults with short follow-up. Older adults face different triggers, including hormones, cosmetics, stress, and prior treatment history.
Follow-up length also matters. Twelve months can miss later relapses that shape adult care. A trial built for teens cannot prove the best long-term total for a 30-year-old woman with years of breakouts.
What does large-scale relapse evidence show?
In 19,907 patients finishing a first isotretinoin course, 22.5 percent had relapse needing further systemic treatment and 8.2 percent took a second isotretinoin course, according to JAMA Dermatology in the large relapse study. Relapse therefore stays common even after a complete course.
Each extra mg/kg lowered relapse risk slightly, but benefit plateaued above about 220 mg/kg. Higher maximum daily doses did not further cut relapse once patients reached at least 120 mg/kg. Female patients had about 43 percent higher relapse hazard than males, a key point for adult women.
What should adults discuss with a dermatologist now?
U.S. dermatology guidance still strongly reserves oral isotretinoin for severe, scarring, burdensome, or treatment-resistant acne. Isotretinoin also remains under the iPLEDGE program because it can cause birth defects, which limits routine higher dosing.
The American Academy of Dermatology describes that narrow role in the updated acne guidelines. Lower daily doses may ease the course for some patients. A 2026 pooled analysis of four trials with 202 patients found similar 24-week results for lower and conventional daily doses, with better tolerability and satisfaction on lower doses. Adults can use the next visit to review specifics: Bring photos, treatment dates, side effects, and pregnancy plans to that visit.
- prior retinoids, antibiotics, hormonal treatments, and response dates
- scarring, pain, dark marks, and effects on work or mood
- dryness, mood changes, lipid or liver issues, and pregnancy plans
You Might Also Like
- Low-Dose Isotretinoin Side Effects in the 2026 Fish Oil Trial: Why the Findings May Not Change Acne Care Yet for Adults With Persistent Acne
- Fish Oil With Low-Dose Isotretinoin in a 2026 Randomized Trial: Why the Findings May Not Change Acne Care Yet for Adults With Persistent Acne
- Why the 2026 Acne Body Image Study Does Not Prove Causation: Study Limits and Care Implications for Young Adults With Acne